Highest-materiality recent filing
Puma Biotech Q1 net loss $3.8M; raises 2026 revenue and net income guidance on NERLYNX demand
Q1 product revenue $42.0M vs $43.1M YoY; GAAP net loss $3.8M ($0.07/share) vs net income $3.0M.
Puma Biotechnology Q4 2025 revenue $75.5M, GAAP net income $13.4M; guides FY2026 net income $10-13M
Q4 2025 product revenue $59.9M (+10% YoY); total revenue $75.5M vs $59.1M YoY including $15.6M royalty.
Puma raises 2025 guidance; Q3 GAAP net income $8.8M vs $20.3M YoY on lower royalty revenue
Q3 GAAP net income $8.8M ($0.17 diluted) vs $20.3M ($0.41) YoY; non-GAAP adj. net income $10.5M ($0.21) vs $22.4M ($0.46).
Puma Biotechnology Q2 net income $5.9M vs year-ago loss; revenue rises to $52.4M
GAAP EPS $0.12 vs $(0.09) loss; adjusted EPS $0.15 vs $(0.05) loss.
Puma swings to Q1 profit; NERLYNX revenue up 7% to $43.1M
GAAP net income $3.0M ($0.06 EPS) vs net loss $4.8M ($0.10 loss) in Q1 2024.
Puma Biotechnology reports Q4 GAAP net income $19.3M ($0.39 EPS); guides FY2025 net income $23-28M
Q4 product revenue net $54.4M (up from $53.2M YoY); full year $195.2M (down from $203.1M).
Puma Biotech Q3 net income $20.3M vs $5.8M YoY; raises FY 2024 guidance
Product revenue $56.1M (+8.7% YoY); total revenue $80.5M including $24.4M royalty revenue.
Puma reports judge invalidated Tagrisso patents; Wyeth appeals Sept 12
Jury awarded $107.5M for past infringement of '314 and '162 patents through Dec 2023.
Court invalidates Puma's patents in Tagrisso suit, overturns $107.5M jury award
Jury found Tagrisso infringed Puma's patents, awarded $107.5M in damages.
Puma Biotechnology wins patent suit vs AstraZeneca; $107.5M jury award upheld in bench trial
Jury found Tagrisso infringes Wyeth's patents; damages of $107.5M for past infringement through Dec 31, 2023.
Puma Q2 NERLYNX revenue $44.4M (-14% YoY); GAAP net loss $4.5M vs profit $2.1M
Q2 2024 product revenue $44.4M (down from $51.6M in Q2 2023); total revenue $47.1M incl $2.7M royalties.
Jury awards Puma/Wyeth $107.5M in Tagrisso patent infringement case vs AstraZeneca
Jury found '314 and '162 patents infringed and not invalid; damages $107.5M for past acts.
Puma Biotech Q1 net loss $4.8M vs prior year net income; NERLYNX revenue down 14%
Net product revenue $40.3M (Q1 2023: $46.8M); total revenue $43.8M including $3.5M royalties.
Puma partially dismissed as plaintiff in Tagrisso patent suit; trial set May 13
Court denied AstraZeneca's motions for patent invalidity and summary judgment of non-infringement.
Puma Biotechnology reports Q4 GAAP net income of $12.3M; guides Q1 2024 net loss of $10-12M
Product revenue net Q4 $53.2M (flat YoY); full year $203.1M, up from $200.0M.
On May 8, 2025, Puma Biotechnology, Inc. (the “Company”) terminated Jeff J. Ludwig as an employee and as its Chief Commercial Officer.
Max materiality 0.85 · Median 0.70 · Most common event earnings